KALA BIO (NASDAQ:KALA) Issues Earnings Results, Beats Estimates By $0.54 EPS

KALA BIO (NASDAQ:KALA) posted its quarterly earnings results on Monday. The company reported ($1.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.28) by $0.54, Zacks reports.

KALA BIO Price Performance

NASDAQ:KALA opened at $5.73 on Tuesday. KALA BIO has a one year low of $4.21 and a one year high of $11.20. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The stock has a market cap of $34.90 million, a P/E ratio of -0.46 and a beta of -2.19. The company has a fifty day moving average price of $7.67 and a 200 day moving average price of $6.81.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research note on Thursday, February 13th.

Insider Buying and Selling at KALA BIO

In related news, CEO Mark T. Iwicki sold 5,779 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the completion of the transaction, the chief executive officer now owns 280,076 shares of the company’s stock, valued at $2,136,979.88. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 9,506 shares of company stock valued at $72,531 in the last quarter. Corporate insiders own 8.32% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.